- Benzinga•yesterdayPuma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program
Puma Biotechnology Inc (NYSE: PBYI ) has had one of its most volatile weeks in recent memory thanks to weak demand for a secondary offering. falling over 28 percent from its Tuesday high of $54.65 To ...
- Business Wire•yesterday
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the underwriters for its public offering of 3,750,000 shares of its common stock at $40.00 per share have elected to exercise in full their option to purchase up to an additional 562,500 shares of common stock at the public offering price, less the underwriting discounts and commissions.
- TheStreet.com•2 days ago
Puma CEO Alan Auerbach wanted the cash desperately, regardless of Puma's stock price. Get the deal done, even if you have to sell it to the shorts.
Puma Biotechnology, Inc. (PBYI)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||43.40 x 100|
|Ask||44.20 x 1200|
|Day's Range||42.55 - 45.75|
|52wk Range||19.74 - 94.93|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.44|
|Avg Vol (3m)||1,088,883|
|Dividend & Yield||N/A (N/A)|